{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:47:13Z","timestamp":1794354433443,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ygyno.2013.06.003","type":"journal-article","created":{"date-parts":[[2013,6,9]],"date-time":"2013-06-09T22:43:12Z","timestamp":1370817792000},"page":"518-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer"],"prefix":"10.1016","volume":"130","author":[{"given":"Kenneth H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor P.","family":"Dmitriev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souheil","family":"Saddekni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Kashentseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond D.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Aurigemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejong","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene P.","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.06.003_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0015","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0020","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(06)68671-6","article-title":"Surgery for ovarian cancer: how to improve survival","volume":"367","author":"Bristow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11912-006-0073-x","article-title":"Gene therapy for ovarian cancer","volume":"8","author":"Kimball","year":"2006","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/14712598.7.9.1347","article-title":"Gene therapy of gynaecological diseases","volume":"7","author":"Kanerva","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0040","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.gt.3301424","article-title":"Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility, and biological activity","volume":"8","author":"Nemunaitis","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0045","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.20.6.1562","article-title":"Phase I trial of intraperitoneal injection of the E1B-55kd-gene deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3weeks in patients with recurrent\/refractory epithelial ovarian cancer","volume":"20","author":"Vasey","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0050","first-page":"813","article-title":"Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary Ad receptors","volume":"61","author":"Douglas","year":"2001","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.ygyno.2013.06.003_bb0055","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0959-8049(02)00131-4","article-title":"The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells","volume":"38","author":"Kim","year":"2002","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2013.06.003_bb0060","first-page":"275","article-title":"Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells","volume":"8","author":"Kanerva","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ygyno.2013.06.003_bb0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1006\/mthe.2002.0599","article-title":"Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses","volume":"5","author":"Kanerva","year":"2002","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ygyno.2013.06.003_bb0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.ygyno.2013.06.003_bb0075","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ygyno.2013.06.003_bb0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ygyno.2013.06.003_bb0085","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/hum.2010.180","article-title":"A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of Ad5\/3-\u039424 in advance of a phase I clinical trial in ovarian cancer patients","volume":"22","author":"Kim","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.ygyno.2013.06.003_bb0110","first-page":"3081","article-title":"A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial","volume":"6","author":"Alvarez","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.003_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.cgt.7700543","article-title":"Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob","volume":"10","author":"Uil","year":"2003","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"10.1016\/j.ygyno.2013.06.003_bb0095","first-page":"3348","article-title":"The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses","volume":"8","author":"Suzuki","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2013.06.003_bb0105","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/hum.1997.8.5-597","article-title":"A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients","volume":"8","author":"Alvarez","year":"1997","journal-title":"Hum Gene Ther"},{"issue":"21","key":"10.1016\/j.ygyno.2013.06.003_bb0115","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-10-0791","article-title":"A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases","volume":"16","author":"Kimball","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ygyno.2013.06.003_bb0120","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-11-2852","article-title":"A phase I clinical trial of Ad5.SSTR\/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer","volume":"18","author":"Kim","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ygyno.2013.06.003_bb0125","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0130","first-page":"1266","article-title":"Treatment of ovarian cancer with a tropism modified oncolytic adenovirus","volume":"62","author":"Bauerschmitz","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.06.003_bb0135","doi-asserted-by":"crossref","first-page":"389e1","DOI":"10.1016\/j.ajog.2006.12.016","article-title":"Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer","volume":"196","author":"Page","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ygyno.2013.06.003_bb0140","first-page":"1915","article-title":"Soluble coxsackie adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu","volume":"8","author":"Bernal","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ygyno.2013.06.003_bb0145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2249.1992.tb06986.x","article-title":"Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects","volume":"89","author":"Hara","year":"1992","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.ygyno.2013.06.003_bb0150","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1128\/JVI.00205-12","article-title":"A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses","volume":"86","author":"Wang","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.06.003_bb0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2007.09.013","article-title":"Oncolytic adenovirus Ad5\/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer","volume":"108","author":"Raki","year":"2008","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813008329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813008329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T07:54:42Z","timestamp":1539590082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813008329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0090825813008329"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718026292.793481389","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}